<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0605257346
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2025
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                         Risek Plus
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OMEPRAZOLE,SODIUM BICARBONATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40,1100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        89.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gulf Pharmaceutical Industries (Julphar)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Risek Plus </strong>capsules<strong> </strong>contain the active substances omeprazole and sodium bicarbonate.</p><p>Omeprazole belongs to a group of medicines called proton pump inhibitors (PPI) and sodium bicarbonate belongs to a group of medicines called antacids.</p><p><strong>Risek Plus </strong>works by reducing the amount of acid in your stomach.</p><p><strong>Risek Plus capsules are used in adults for:</strong></p><p>&middot;&nbsp;&nbsp; up to 8 weeks for the healing of duodenal ulcers.</p><p>&middot;&nbsp;&nbsp; up to 8 weeks for the healing of stomach ulcers.</p><p>&middot;&nbsp;&nbsp; up to 4 weeks to treat heartburn and other symptoms that happen with gastroesophageal reflux disease (GERD).</p><p>&middot;&nbsp;&nbsp; up to 8 weeks for the healing and symptom relief of acid-related damage to the lining of the esophagus (called erosive esophagitis or EE). Your doctor may prescribe another 4 weeks of <strong>Risek Plus </strong>in patients whose EE does not heal.</p><p>&middot;&nbsp;&nbsp; maintaining healing of EE and to help prevent the return of heartburn symptoms caused by GERD. It is not known if this medicine is safe and effective when used for longer than 12 months for this purpose.</p><p>It is not known if this medicine is safe and effective in children.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Risek Plus if you are:</strong></p><p>&middot;&nbsp;&nbsp; allergic to omeprazole, any other PPI medicine, or any of the ingredients in <strong>Risek Plus</strong>. See section no.6 (Further information) for a complete list of ingredients in <strong>Risek Plus</strong>.&nbsp;</p><p>&middot;&nbsp;&nbsp; taking a medicine that contains rilpivirine, used to treat HIV-1 (Human Immunodeficiency Virus).</p><p><strong>Before taking Risek Plus, tell your doctor about all of your medical conditions, including if you:</strong></p><p>&middot;&nbsp;&nbsp; have low magnesium, calcium, or potassium levels in your blood.</p><p>&middot;&nbsp;&nbsp; have problems with the acid-base (pH) balance in your body.</p><p>&middot;&nbsp;&nbsp; have liver problems.</p><p>&middot;&nbsp;&nbsp; have heart failure.</p><p>&middot;&nbsp;&nbsp; are on a low-sodium diet.</p><p>&middot;&nbsp;&nbsp; have Bartter&rsquo;s syndrome (a rare kidney problem).</p><p>&middot;&nbsp;&nbsp; are of Asian descent and have been told that your body&rsquo;s ability to break down (metabolize) omeprazole is poor or if your genotype called CYP2C19 is not known.</p><p>&middot;&nbsp;&nbsp; you are due to have specific blood test (Chromogranin A).</p><p>&middot;&nbsp;&nbsp; are pregnant or plan to become pregnant. It is not known if this medicine<strong> </strong>will harm your unborn baby.</p><p>&middot;&nbsp;&nbsp; are breastfeeding or plan to breastfeed. Omeprazole and sodium bicarbonate can pass into your breast milk. Talk with your doctor about the best way to feed your baby if you take <strong>Risek Plus</strong>.<strong> </strong></p><p>&middot;&nbsp;&nbsp; <strong>Presence of Gastric Malignancy</strong></p><p>In adults, symptomatic response to therapy with <strong>Risek Plus</strong> does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing in adult patients who have a suboptimal response or an early symptomatic relapse after completing treatment with a proton pump inhibitor (PPI). In older patients, also consider an endoscopy.</p><p><strong>Receiving treatment with PPI such as omeprazole has been associated with the following conditions: </strong></p><p>&middot;&nbsp;&nbsp; <strong>Acute Tubulointerstitial Nephritis: </strong>Contact your doctor immediately if you experience signs and/or symptoms associated with acute tubulointerstitial nephritis such decrease urination or blood in the urine and/or hypersensitivity reactions such as fever, rash, and joint stiffness.</p><p>&middot;&nbsp;&nbsp; <strong>Clostridium difficile-Associated Diarrhea: </strong>Contact your doctor immediately if you experience diarrhea that does not improve.</p><p>&middot;&nbsp;&nbsp; <strong>Bone Fracture: </strong>Inform your doctor, if you experience any fractures, especially of the hip, wrist or spine.</p><p>The risk of fracture increases with high-dose and long-term of PPI treatment (a year or longer).</p><p>Tell your doctor if you have osteoporosis or if you are taking corticosteroids (which can increase the risk of osteoporosis).</p><p>&middot;&nbsp;&nbsp; <strong>Severe Cutaneous Adverse Reactions: </strong>inform your doctor immediately at first appearance of a severe cutaneous adverse reaction or other sign of hypersensitivity.</p><p>&middot;&nbsp;&nbsp; <strong>Cutaneous and Systemic Lupus Erythematosus: </strong>Contact your doctor immediately if you experience or worsening of symptoms associated with cutaneous or systemic lupus erythematosus such as joint pain or a rash.</p><p>&middot;&nbsp;&nbsp; <strong>Vitamin B<sub>12</sub> Deficiency: </strong>if you have been receiving <strong>Risek Plus </strong>for longer than 3 years, you should inform your doctor about any symptoms that may be associated with vitamin B<sub>12</sub> deficiency (See section 4).</p><p>&middot;&nbsp;&nbsp; <strong>Hypomagnesemia and Mineral Metabolism: </strong>if you have been receiving <strong>Risek Plus </strong>for at least 3 months<strong>, </strong>you should inform your doctor about any symptoms that may be associated with hypomagnesemia, hypocalcemia, and/or hypokalemia.</p><p>&middot;&nbsp;&nbsp; <strong>I</strong><strong>nteractions with Diagnostic Investigations for Neuroendocrine Tumors:</strong><strong> </strong>Increased Chromogranin A (CgA) levels may interfere with diagnostic investigations for neuroendocrine tumors; temporarily stop <strong>Risek Plus </strong>at least 14 days before assessing CgA levels.</p><p>&middot;&nbsp;&nbsp; Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Especially tell your doctor if you take:</p><p>-&nbsp;&nbsp;&nbsp; rilpivirine, atazanavir, nelfinavir, saquinavir</p><p>-&nbsp;&nbsp;&nbsp; mycophenolate mofetil</p><p>-&nbsp;&nbsp;&nbsp; ketoconazole/itraconazole</p><p>-&nbsp;&nbsp;&nbsp; erlotinib, dasatinib, nilotinib</p><p>-&nbsp;&nbsp;&nbsp; products that contains iron</p><p>-&nbsp;&nbsp;&nbsp; cyclosporin</p><p>-&nbsp;&nbsp;&nbsp; disulfiram</p><p>-&nbsp;&nbsp;&nbsp; tacrolimus</p><p>-&nbsp;&nbsp;&nbsp; warfarin</p><p>-&nbsp;&nbsp;&nbsp; digoxin</p><p>-&nbsp;&nbsp;&nbsp; clopidogrel, citalopram, cilostazol, phenytoin, diazepam</p><p>-&nbsp;&nbsp;&nbsp; St. John&rsquo;s wort (Hypericum perforatum)</p><p>-&nbsp;&nbsp;&nbsp; rifampin</p><p>-&nbsp;&nbsp;&nbsp; ritonavir</p><p>-&nbsp;&nbsp;&nbsp; voriconazole</p><p>-&nbsp;&nbsp;&nbsp; methotrexate</p><p>Ask your doctor or pharmacist for a list of these medicines, if you are not sure.</p><p>Know the medicines that you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.</p><p><strong>Sodium Bicarbonate Content</strong></p><p>Take this medicine with caution if you are on a sodium-restricted diet or at risk of developing congestive heart failure, as it contains sodium.</p><p><u>The following should be taken into consideration: </u></p><p>&middot;&nbsp;&nbsp; Long-term use of bicarbonate with calcium or milk can cause milk-alkali syndrome</p><p>&middot;&nbsp;&nbsp; Long-term use of sodium bicarbonate may lead to systemic alkalosis</p><p>&middot;&nbsp;&nbsp; Increased sodium intake can cause swelling and weight gain.</p><p>If any of these occur, please contact your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>3.&nbsp; How to take Risek Plus </strong></p><p>Take <strong>Risek Plus </strong>exactly as prescribed by your doctor.</p><p>Do not change your dose or stop taking <strong>Risek Plus </strong>without talking to your doctor.</p><p>Swallow <strong>Risek Plus </strong>capsules whole with water. Do not use other liquids. Do not crush or chew the capsule. Do not open the capsule and sprinkle contents into food.&nbsp;</p><p>Take <strong>Risek Plus </strong>capsules on an empty stomach at least 1 hour before a meal.</p><p><strong>All recommended dosages are based upon omeprazole content.</strong></p><p><strong>Recommended dosage regimen of Risek Plus capsules in adults by Indications:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Indications</p></td><td><p>Dosage of Risek Plus capsules</p></td><td><p>Treatment Duration</p></td></tr><tr><td><p>Treatment of Active Duodenal Ulcer</p></td><td><p>20mg once daily</p></td><td><p>4 weeks1</p></td></tr><tr><td><p>Treatment of Active Benign Gastric Ulcer</p></td><td><p>40mg once daily</p></td><td><p>4 to 8 weeks</p></td></tr><tr><td><p>Treatment of Symptomatic GERD</p></td><td><p>20mg once daily</p></td><td><p>Up to 4 weeks</p></td></tr><tr><td><p>Treatment of EE due to Acid Mediated GERD</p></td><td><p>20mg once daily</p></td><td><p>4 to 8 weeks2</p></td></tr><tr><td><p>Maintenance of Healing of EE due to Acid-Mediated GERD</p></td><td><p>20mg once daily</p></td><td><p>Controlled studies do not extend beyond 12 months.</p></td></tr></tbody></table><p><sup>1 &nbsp;&nbsp;&nbsp;&nbsp; </sup>Most patients heal within 4 weeks. Some patients may require an additional 4 weeks of therapy.</p><p><sup>2 &nbsp;&nbsp;&nbsp;&nbsp; </sup>The efficacy of Omeprazole/ Sodium bicarbonate used for longer than 8 weeks in patients with EE has not been established.</p><p>If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8-week courses of <strong>Risek Plus</strong> capsules may be considered.</p><p><strong>If you take more Risek Plus than you should&nbsp; </strong></p><p>Do not substitute two 20 mg capsules for one 40 mg capsule of <strong>Risek Plus</strong> because you will receive twice the amount of sodium bicarbonate. Talk to your doctor if you have questions.</p><p>If you take too much <strong>Risek Plus</strong>, call your doctor or go to the nearest hospital emergency room</p><p><strong>If you forget to take Risek Plus</strong></p><p>If you miss a dose of <strong>Risek Plus</strong>, take it as soon as you remember. If it is almost time for your next dose, do not take the missed dose. Take the next dose at your regular time. Do not take two doses to make up for a missed dose.</p><p><strong>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Risek Plus</strong> may help your acid-related symptoms, but you could still have serious stomach problems. Talk with your doctor.</p><p><strong>Risek Plus</strong> <strong>can cause serious side effects, including:</strong></p><p>&middot;&nbsp;&nbsp; A type of kidney problem (acute tubulointerstitial nephritis). Some people who take proton pump inhibitor (PPI) medicines, including omeprazole, may develop a kidney problem called acute tubulointerstitial nephritis that can happen at any time during treatment with <strong>Risek Plus</strong>. &nbsp;</p><p>Call your doctor right away if you have a decrease in the amount that you urinate or if you have blood in your urine.</p><p>&middot;&nbsp;&nbsp; <strong>Risek Plus</strong> contains sodium bicarbonate. Long-term use of bicarbonate with calcium or milk can cause a condition called &ldquo;milk-alkali syndrome&rdquo;. Long-term use of sodium bicarbonate can cause a condition called &ldquo;systemic alkalosis&rdquo;. Talk to your doctor about any questions you may have. Too much sodium can cause swelling and weight gain. Tell your doctor if you are on a low-sodium diet or if you have Bartter&rsquo;s Syndrome (a rare kidney disorder).Tell your doctor right away if you have confusion, shaking hands, dizziness, muscle twitching, nausea, vomiting, and numbness or tingling in the face, arms, or legs.</p><p>&middot;&nbsp;&nbsp; Diarrhea caused by an infection (Clostridium difficile) in your intestines. Call your doctor right away if you have watery stools or stomach pain that does not go away. You may or may not have a fever.</p><p>&middot;&nbsp;&nbsp; Bone fractures (hip, wrist, or spine). Bone fractures in the hip, wrist or spine may happen in people who take multiple daily doses of PPI medicines and for a long period of time (a year or longer). Tell your doctor if you have bone fracture, especially in the hip, wrist, or spine.</p><p>&middot;&nbsp;&nbsp; Certain types of lupus erythematosus. Lupus erythematosus is an autoimmune disorder (the body&rsquo;s immune cells attack other cells or organs in the body). Some people who take PPI medicines, including omeprazole, may develop certain types of lupus erythematosus or have worsening of the lupus they already have. Call your doctor right away if you have new or worsening joint pain or a rash on your cheeks or arms that gets worse in the sun.</p><p>Talk to your doctor about your risk of these serious side effects.</p><p>&middot;&nbsp;&nbsp; Low vitamin B<sub>12</sub> levels in your body can happen in people who have taken this medicine for a long time (more than 3 years).Tell your doctor if you have symptoms of low vitamin B<sub>12</sub> levels, including shortness of breath, lightheadedness, irregular heartbeat, muscle weakness, pale skin, feeling tired, mood changes, and tingling or numbness in the arms and legs.</p><p>&middot;&nbsp;&nbsp; Low magnesium levels in your body can happen in people who have taken this medicine for at least 3 months. Tell your doctor right away if you have symptoms of low magnesium levels, including seizures, dizziness, irregular heartbeat, jitteriness, muscle aches or weakness, and spasms of hands, feet or voice.</p><p>&middot;&nbsp;&nbsp; Stomach growths (fundic gland polyps). People who take PPI medicines for a long time have an increased risk of developing a certain type of stomach growths called fundic gland polyps, especially after taking PPI medicines for more than 1 year.</p><p>&middot;&nbsp;&nbsp; Severe skin reactions. This medicine can cause rare but severe skin reactions that may affect any part of your body. These serious skin reactions may need to be treated in a hospital and may be life threatening:</p><p>&ndash;&nbsp;&nbsp; Skin rash which may have blistering, peeling or bleeding on any part of your skin (including your lips, eyes, mouth, nose, genitals, hands or feet).</p><p>&ndash;&nbsp;&nbsp; &nbsp;You may also have fever, chills, body aches, shortness of breath, or enlarged lymph nodes.</p><p>Stop taking <strong>Risek Plus </strong>and call your doctor right away. These symptoms may be the first sign of a severe skin reaction.</p><p><strong>The most common side effects of this medicine include:</strong></p><p>&middot;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp; abdominal pain</p><p>&middot;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp; diarrhea</p><p>&middot;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp; gas</p><p><strong><u>Reporting of side effects</u></strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via:</p><p><strong>Saudi Arabia:</strong></p><p><strong>&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</strong></p><p><strong>&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp; SFDA Call Centre:</strong> 19999</p><p><strong>&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp; E-mail:</strong> npc.drug@sfda.gov.sa</p><p><strong>&nbsp;&nbsp;&nbsp; -&nbsp;&nbsp;&nbsp; Website: </strong>https://ade.sfda.gov.sa/</p><p><strong>Other GCC States:</strong></p><p>&nbsp;&nbsp;&nbsp; <strong>-</strong>&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p>By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&ndash;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>&ndash;&nbsp;&nbsp; Do not take <strong>Risek Plus</strong> after the expiry date which is stated on the carton and inner label.</p><p>&ndash;&nbsp;&nbsp; Store below 30&deg;C, protected from light and moisture.</p><p>&ndash;&nbsp;&nbsp; Keep container tightly closed.</p><p>&ndash;&nbsp;&nbsp; Do not take Risek Plus if you notice any visible sign of deterioration.</p><p>&ndash;&nbsp;&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredients: Omeprazole and Sodium bicarbonate.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><strong><u>Risek Plus 20mg/1100mg capsules:</u></strong></p><p>Each hard gelatin capsule contains: Omeprazole 20mg / Sodium bicarbonate 1100mg.</p><p>The other ingredients are: croscarmellose sodium, magnesium stearate, titanium dioxide and gelatin.</p><p><strong><u>Risek Plus 40mg/1100mg capsules:</u></strong></p><p>Each hard gelatin capsule contains: Omeprazole 40mg / Sodium bicarbonate 1100mg.</p><p>The other ingredients are: croscarmellose sodium, magnesium stearate, titanium dioxide and gelatin.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Risek Plus is hard gelatin capsule, size “00EL” containing white to off- white powder
Risek Plus 20mg/1100mg capsules:
Cap: White opaque, printed “Julphar” radial in black. 
Body: White opaque, printed “OS20” radial in black.

Risek Plus 40mg/1100mg capsules:
Cap: White opaque, printed “Julphar” radial in black. 
Body: White opaque, printed “OS40” radial in black.

Risek Plus 20mg/1100mg capsules are available in packs of 14 or 30 hard gelatin capsules (in a HDPE container).
Risek Plus 40mg/1100mg capsules are available in packs of 14 or 30 hard gelatin capsules (in a HDPE container).

* Not all pack sizes may be marketed

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gulf Pharmaceutical Industries &quot; Julphar&quot;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                22/07/2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي <strong>رايسك بلس</strong> على المواد الفعالة أوميبرازول وبيكربونات الصوديوم.</p><p dir="RTL">ينتمي أوميبرازول إلى المجموعة الدوائية التي تعرف باسم مثبطات مضخة البروتون وينتمي بيكربونات الصوديوم إلى المجموعة الدوائية التي&nbsp; تعرف باسم مضادات الحموضة.</p><p dir="RTL">يعمل <strong>رايسك بلس </strong>على خفض كمية الحمض الذي تنتجه المعدة.</p><p dir="RTL"><strong>تستخدم كبسولات رايسك بلس من قبل البالغون في الحالات التالية: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; لمدة تصل إلى 8 أسابيع لعلاج حالات قرحة الاثني عشر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; لمدة تصل إلى 8 أسابيع لعلاج حالات قرحة المعدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; لمدة تصل إلى 4 أسابيع لعلاج حرقة المعدة والأعراض الأخرى التي تحدث مع داء الارتجاع المعدي المريئي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; لمدة تصل إلى 8 أسابيع لعلاج وتخفيف الأعراض الناجمة عن الأضرار المرتبطة بالحمض لبطانة المريء (تعرف باسم التهاب المريء التآكلي). قد يصف الطبيب المعالج بتلقي العلاج باستخدام <strong>رايسك بلس</strong> لمدة 4 أسابيع إضافية للمرضى في حال عدم شفاء حالة التهاب المريء التآكلي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; الوقاية من عدم تكرار حدوث التهاب المريء التآكلي وأعراض حرقة المعدة الناجمة عن داء الارتجاع المعدي المريئي. لم يتم معرفة مدى سلامة وفعالية استخدام هذا الدواء لمدة تتجاوز عن 12 شهراً.</p><p dir="RTL">لم يتم معرفة مدى سلامة وفعالية استخدام هذا الدواء من قبل الأطفال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عليك عدم تناول رايسك بلس في الحالات التالية:</strong></p><p dir="RTL">إذا كنت تعاني من الحساسية تجاه أوميبرازول، أياً من الأدوية الأخرى من مجموعة مثبطات مضخة البروتون أو تجاه أياً من المكونات الأخرى في <strong>رايسك بلس. </strong>يرجى الرجوع إلى البند رقم 6 (معلومات إضافية) لمعرفة جميع المكونات المتواجدة في <strong>رايسك بلس.</strong></p><p dir="RTL">إذا كنت تتناول أية أدوية تحتوي على مادة ريلبيفيرين، الذي يستخدم لعلاج فيروس عوز المناعة البشري - 1.</p><p dir="RTL"><strong>يرجى منك إخبار طبيبك المعالج حول جميع الحالات المرضية التي تعاني منها قبل تناول رايسك بلس وبما في ذلك ما يلي: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من انخفاض مستويات المغنيسيوم، الكالسيوم أو البوتاسيوم في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اضطراب في&nbsp;التوازن&nbsp;الحمضي القاعدي في الجسم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اضطرابات في الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من فشل في القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كنت تتبع نظاماً غذائياً منخفض الصوديوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من متلازمة بارتر (اضطراب نادر في الكلى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كنت من الأصول الآسيوية وقد تم إخبارك ببطء عملية أيض أوميبرازول لديك أو أن النمط الجيني لإنزيم سيتوكروم 2 سي 19 لديك غير معروف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كنت على وشك القيام بأحد فحوصات الدم (كروموجرانين أ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملاً أو تخططين لذلك. لم يعرف ما إذا كان هذا الدواء قد يلحق ضرراً للجنين.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا كنتِ ترضعين طفلك رضاعة طبيعية أو تخططين لذلك. من الممكن أن يفرز أوميبرازول وبيكربونات الصوديوم في حليب الثدي. يرجى منك استشارة طبيبك المعالج للحصول على المشورة حول أفضل وسيلة لإرضاع طفلك إذا كنت تتناولين <strong>رايسك بلس</strong>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; <strong>وجود ورم خبيث في المعدة</strong></p><p dir="RTL">إن استجابة المرضى البالغين للعلاج باستخدام<strong> رايسك بلس </strong>لا يحول دون حدوث<strong> </strong>ورم خبيث في المعدة.<strong> </strong></p><p dir="RTL">يجب الأخذ بعين الاعتبار المتابعة بشكل دوري وإجراء الفحوصات التشخيصية للمرضى البالغين الذين يعانون من استجابة دون المستوى المطلوب أو في حال معاودة حدوث الأعراض مبكراً بعد استكمال العلاج بمثبط مضخة البروتون. كما يجب أيضاً مراعاة ذلك لدى المرضى كبار السن عن طريق إجراء الفحص بالتنظير.</p><p dir="RTL"><strong>سجل حدوث الحالات التالية عند تلقي العلاج باستخدام مثبطات مضخة البروتون على سبيل المثال أوميبرازول:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; <strong>التهاب الكلية الخلالي الأنبوبي الحاد</strong>: يرجى منك التواصل مع طبيبك المعالج على الفور، في حال ظهور علامات و/أو أعراض مصاحبة لالتهاب الكلية الخلالي الأنبوبي الحاد على سبيل المثال قلة التبول أو ظهور دم في البول و/أو تفاعلات فرط الحساسية على سبيل المثال حمى، طفح جلدي و تصلب المفاصل.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; <strong>الإسهال المرتبط بعدوى الكلوستريديوم ديفيسيل</strong>: يرجى منك التواصل مع طبيبك المعالج على الفور، إذا عانيت من تفاقم حالة الإسهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; <strong>حدوث كسر في العظام</strong>: يرجى منك إخبار طبيبك المعالج إذا عانيت من حالة كسر في العظم، وبصفة خاصة عظم الورك والمعصم أو العمود الفقري.</p><p dir="RTL">يزداد خطر حدوث كسر في العظام عند تلقي العلاج باستخدام جرعات كبيرة من مثبطات مضخة البروتون أو لفترة زمنية طويلة (لمدة سنة واحدة أو أكثر).</p><p dir="RTL">يرجى منك إخبار طبيبك المعالج إذا كنت تعاني من هشاشة العظام أو إذا كنت تتناول أياً من الكورتيكوستيرويدات (التي قد تزيد من خطر حدوث هشاشة العظام).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; <strong>ردود الفعل العكسية الجلدية الشديدة</strong>: يرجى منك إخبار طبيبك المعالج على الفور عند أول ظهور لرد فعل جلدي شديد أو ظهور أية علامة أخرى لفرط الحساسية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; <strong>الذئبة الحمامية الجلدية والجهازية:</strong> يرجى منك التواصل مع طبيبك المعالج على الفور، إذا عانيت من الأعراض المصاحبة للذئبة الحمامية الجلدية أو الجهازية على سبيل المثال ألم في المفاصل أو طفح جلدي أو تفاقم حالة الذئبة الحمامية القائمة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; <strong>نقص فيتامين ب<sub>12</sub></strong>: إذا كنت تتلقى <strong>رايسك بلس </strong>لمدة تتجاوز عن 3 سنوات، فيجب عليك إخبار طبيبك المعالج عن أية أعراض قد تكون مصاحبة لنقص فيتامين ب<sub>12</sub> (انظر البند رقم 4).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; <strong>نقص مغنيسيوم الدم والأيض المعدني</strong>: إذا كنت تتلقى <strong>رايسك بلس </strong>لمدة لا تقل عن 3 أشهر، فيجب عليك إخبار طبيبك المعالج عن أية أعراض قد تكون مصاحبة لنقص مستويات المغنيسيوم في الدم، نقص مستويات الكالسيوم في الدم و/أو نقص مستويات البوتاسيوم في الدم .</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp; </strong><strong>التفاعلات مع الفحوصات التشخيصية لأورام الغدد العصبية الصماء: </strong>قد يؤثر ارتفاع مستويات كروموجرانين أ على الفحوصات التشخيصية لأورام الغدد العصبية الصماوية؛ يجب التوقف عن تلقي العلاج باستخدام <strong>رايسك بلس</strong> بشكل مؤقت 14 يوماً على الأقل قبل إجراء فحص قياس مستويات كروموجرانين أ.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp; </strong>يرجى منك إخبار طبيبك المعالج حول جميع الأدوية التي تقوم بتناولها، بما في ذلك الأدوية التي تصرف بواسطة الطبيب المعالج، الأدوية التي تصرف دون وصفة طبية، الفيتامينات والمكملات العشبية. بصفة خاصة، يرجى منك إخبار طبيبك المعالج إذا كنت تتناول أياً من الأدوية التالية:</p><p dir="RTL">-&nbsp;&nbsp; ريلبيفيرين، أتازانافير، نيلفينافير، ساكوينافير</p><p dir="RTL">-&nbsp;&nbsp; مايكوفينولات موفيتيل</p><p dir="RTL">-&nbsp;&nbsp; كيتوكونازول/إتراكونازول</p><p dir="RTL">-&nbsp;&nbsp; إيرلوتينيب، داساتينيب، نيلوتينيب</p><p dir="RTL">-&nbsp;&nbsp; المنتجات التي تحتوي على الحديد</p><p dir="RTL">-&nbsp;&nbsp; سيكلوسبورين</p><p dir="RTL">-&nbsp;&nbsp; ديسلفرام</p><p dir="RTL">-&nbsp;&nbsp; تاكروليمس</p><p dir="RTL">-&nbsp;&nbsp; وارفارين</p><p dir="RTL">-&nbsp;&nbsp; ديجوكسين</p><p dir="RTL">-&nbsp;&nbsp; كلوبيدوغريل، سيتالوبرام، سيلوستازول، فينيتوين، ديازيبام.</p><p dir="RTL">-&nbsp;&nbsp; نبتة سانت جون (هايبيريكم بيرفراتم)</p><p dir="RTL">-&nbsp;&nbsp; ريفامبين</p><p dir="RTL">-&nbsp;&nbsp; ريتونافير</p><p dir="RTL">-&nbsp;&nbsp; فوريكونازول</p><p dir="RTL">-&nbsp;&nbsp; ميثوتركسيت</p><p dir="RTL">يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه حول الأدوية التي تقوم بتناولها، في حال لم تكن متأكداً من ذلك.</p><p dir="RTL">يجب عليك معرفة الأدوية التي تقوم بتناولها. يرجى وضع قائمة تحتوي على جميع الأدوية التي تتناولها لإظهارها لطبيبك المعالج أو الصيدلي الذي تتعامل معه عندما يتم وصف دواءً جديداً لك.</p><p dir="RTL"><strong>يحتوي هذا الدواء على بيكربونات الصوديوم </strong></p><p dir="RTL">يجب توخي الحذر عند تناول هذا الدواء، إذا كنت تتبع نظاماً غذائياً للتحكم في كمية الصوديوم أو كنت معرضاً لخطر حدوث فشل القلب الاحتقاني، نظراً لاحتواء هذا الدواء على الصوديوم.</p><p dir="RTL"><u>يجب مراعاة ما يلي: </u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; يؤدي استعمال بيكربونات بالتزامن مع الكالسيوم أو الحليب لفترة زمنية طويلة إلى حدوث متلازمة&nbsp;الحليب القلوي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; يؤدي استعمال بيكربونات الصوديوم لفترة زمنية طويلة إلى حدوث فرط قلوية الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; يؤدي زيادة استعمال الصوديوم إلى حدوث تورم وزيادة الوزن.</p><p dir="RTL">يرجى منك التواصل مع طبيبك المعالج، في حال حدوث أياً مما ذكر أعلاه.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب عليك تناول <strong>رايسك بلس </strong>بدقة وفقاً لتعليمات طبيبك المعالج.</p><p dir="RTL">يجب عليك عدم تغيير مقدار الجرعة أو التوقف عن تناول <strong>رايسك بلس </strong>دون استشارة طبيبك المعالج.</p><p dir="RTL">قم بابتلاع كبسولات <strong>رايسك بلس </strong>كاملة مع الماء. يجب عدم تناول أي أنواع أخرى من السوائل. يجب عليك عدم سحق أو مضغ الكبسولة. يجب عليك عدم إفراغ محتوى الكبسولة ووضعها على الطعام.</p><p dir="RTL">قم بتناول كبسولات <strong>رايسك بلس </strong>على<strong> </strong>معدة خالية لمدة لا تقل عن ساعة واحدة قبل تناول وجبة الطعام.</p><p dir="RTL"><strong>يعتمد مقدار جميع الجرعات الموصى على أوميبرازول.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نظام الجرعات الموصى بها وفقاً لدواعي استعمال رايسك بلس للبالغين:</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:341px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong><sup>دواعي الاستعمال</sup></strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong><sup>مقدار الجرعة من كبسولات رايسك بلس</sup></strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong><sup>مدة العلاج</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><sup>لعلاج حالات قرحة الاثني عشر.</sup></p></td><td style="vertical-align:top"><p dir="RTL"><sup>20 ملغم مرة واحدة يومياً</sup></p></td><td style="vertical-align:top"><p dir="RTL"><sup>4 أسابيع1</sup></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><sup>لعلاج حالات قرحة المعدة القائمة الحميدة</sup></p></td><td style="vertical-align:top"><p dir="RTL"><sup>40 ملغم مرة واحدة يومياً</sup></p></td><td style="vertical-align:top"><p dir="RTL"><sup>4 إلى 8 أسابيع</sup></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><sup>لعلاج أعراض داء الارتجاع المعدي المريئي</sup></p></td><td style="vertical-align:top"><p dir="RTL"><sup>20 ملغم مرة واحدة يومياً</sup></p></td><td style="vertical-align:top"><p dir="RTL"><sup>تصل إلى 4 أسابيع</sup></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><sup>لعلاج التهاب المريء التآكلي الناجم عن ارتجاع المريء الحمضي</sup></p></td><td style="vertical-align:top"><p dir="RTL"><sup>20 ملغم مرة واحدة يومياً</sup></p></td><td style="vertical-align:top"><p dir="RTL"><sup>4 إلى 8 أسابيع2</sup></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><sup>للوقاية من عدم تكرار حدوث التهاب المريء التآكلي الناجم عن&nbsp; ارتجاع المريء الحمضي</sup></p></td><td style="vertical-align:top"><p dir="RTL"><sup>20 ملغم مرة واحدة يومياً</sup></p></td><td style="vertical-align:top"><p dir="RTL"><sup>لم تتجاوز الدراسات الخاضعة للرقابة عن 12 شهراً.</sup></p></td></tr></tbody></table><p dir="RTL"><sup>1 </sup>يستغرق معدل شفاء المرضى في غضون 4 أسابيع. قد يتطلب إلى تلقي العلاج لمدة 4 أسابيع إضافية من قبل بعض المرضى.</p><p dir="RTL"><sup>2 </sup>إن<sup> </sup>مدى فاعلية استخدام أوميبرازول / بيكربونات الصوديوم لمدة تتجاوز عن 8 أسابيع من قبل المرضى الذين يعانون من حدوث التهاب المريء التآكلي غير معروفة.</p><p dir="RTL">في حال عدم تحسن الحالة المرضية لدى المرضى الذين تلقوا العلاج لمدة 8 أسابيع، فيمكن تلقي العلاج لمدة 4 أسابيع إضافية. في حال معاودة حدوث الأعراض الناجمة عن التهاب المريء التآكلي أو داء الارتجاع المعدي المريئي (على سبيل المثال حرقة المعدة)، فمن الممكن تلقي العلاج باستخدام<strong> رايسك بلس</strong> لمدة تتراوح ما بين 4 إلى 8 أسابيع.</p><p dir="RTL"><strong>إذا تناولت رايسك بلس بجرعة أكبر مما يجب </strong></p><p dir="RTL">يجب عدم استبدال جرعة من <strong>رايسك بلس</strong> مقدارها كبسولة واحدة 40 ملغم بجرعة مقدارها كبسولتين 20 ملغم، ذلك لأنه قد تتناول ضعف مقدارالجرعة من بيكربونات الصوديوم. يرجى منك التحدث إلى طبيبك المعالج، إذا كان لديك أية أسئلة. يرجى منك التواصل مع طبيبك المعالج أو التوجه إلى غرفة الطوارئ في أقرب مستشفى، إذا تناولت جرعة مفرطة من <strong>رايسك بلس</strong>.</p><p dir="RTL"><strong>إذا سهوت عن تناول رايسك بلس</strong></p><p dir="RTL">إذا سهوت عن تناول إحدى جرعات<strong> رايسك بلس</strong>، فيجب عليك تناولها في أسرع وقت ممكن حال تذكرها. في حال اقتراب موعد تناول الجرعة التالية، فيجب عليك التخطي عن تناول الجرعة التي قد سهوت عن تناولها وتناول الجرعة التالية في وقتها كما هو معتاد. يجب عليك عدم مضاعفة مقدار الجرعة للتعويض عن الجرعة التي قد سهوت عن تناولها.</p><p dir="RTL"><strong>يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه، إذا كان لديك أية أسئلة إضافية حول استعمال هذا الدواء.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو عليه الحال مع جميع الأدوية، قد يتسبب هذا الدواء في حدوث تأثيرات جانبية، على الرغم من أنها قد لا تحدث لكل شخص.</p><p dir="RTL">قد يعمل <strong>رايسك بلس</strong> على علاج الأعراض المرتبطة بارتفاع كمية الحمض الذي تنتجه المعدة، ولكن على الرغم من ذلك من الممكن أن تصاب بمشاكل خطيرة في المعدة. يرجى منك التحدث مع طبيبك المعالج.</p><p dir="RTL"><strong>من الممكن أن يسبب رايسك بلس في حدوث التأثيرات الجانبية التالية: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إحدى اضطرابات الكلى (التهاب الكلية الخلالي الحاد). قد يعاني بعض الأشخاص الذين يتلقون مثبطات مضخة البروتون بما في ذلك أوميبرازول من اضطراب في الكلى يعرف باسم التهاب الكلية الخلالي الحاد الذي من الممكن أن يحدث في أي وقت أثناء فترة تلقي العلاج باستخدام <strong>رايسك بلس</strong>.</p><p dir="RTL">يرجى منك التواصل مع طبيبك المعالج على الفور إذا عانيت من قلة التبول أو ظهور دم في البول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; يحتوي <strong>رايسك بلس</strong> على بيكربونات الصوديوم. يؤدي استعمال بيكربونات بالتزامن مع الكالسيوم أو الحليب لفترة زمنية طويلة إلى حدوث متلازمة&nbsp;الحليب القلوي. يؤدي استعمال بيكربونات الصوديوم لفترة زمنية طويلة إلى حدوث حالة مرضية تعرف باسم &laquo;فرط قلوية الدم&raquo;. يرجى منك التحدث إلى طبيبك المعالج، إذا كان لديك أية أسئلة إضافية. يؤدي زيادة استعمال الصوديوم إلى حدوث تورم وزيادة الوزن. يرجى منك إخبار طبيبك المعالج إذا كنت تتبع نظاماً غذائياً منخفض الصوديوم أو إذا كنت تعاني من متلازمة بارتر (اضطراب نادر في الكلى). يرجى منك إخبار طبيبك المعالج على الفور إذا كنت تعاني من ارتباك، ارتعاش اليدين، دوخة، ارتعاش العضلات، غثيان، تقيؤ وتنميل أو تخدر في الوجه، الذراعين أو الساقين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; الإسهال الناجم عن العدوى (الكلوستريديوم ديفيسيل) في الأمعاء. يرجى منك التواصل مع طبيبك المعالج على الفور إذا عانيت من&nbsp; براز مائي أو ألم في المعدة والذي لا تتحسن حالته. قد تعاني أو لا تعاني من الحمى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; كسور في العظم (الورك، المعصم أو العمود الفقري). قد يحدث كسور في عظم الورك، المعصم أو العمود الفقري لدى الأشخاص الذين يتلقون العلاج باستخدام جرعات يومية مضاعفة من مثبطات مضخة البروتون ولفترة زمنية طويلة (لمدة سنة أو أكثر). يرجى منك إخبار طبيبك المعالج إذا كنت تعاني من كسر في العظم، وبصورة خاصة في عظم الورك، المعصم أو العمود الفقري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; أنواع معينة من الذئبة الحمامية. الذئبة الحمامية هي إحدى الاضطرابات المناعية الذاتية (عندما تقوم الخلايا المناعية في الجسم بمهاجمة الخلايا الأخرى أو الأعضاء في الجسم). قد يعاني بعض الأشخاص الذين يتلقون مثبطات مضخة البروتون بما في ذلك أوميبرازول من أنواع معينة من الذئبة الحمامية أو تفاقم حالة الذئبة الحمامية القائمة. يرجى منك التواصل مع طبيبك المعالج على الفور، في حال تفاقم أو ظهور ألم في المفاصل أو طفح جلدي في الخدين أو الذراعين والذي يزداد سوءاً عند التعرض للشمس.</p><p dir="RTL">يرجى منك التحدث إلى طبيبك المعالج حول مدى خطر حدوث تلك التأثيرات الجانبية الخطيرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; قد يحدث انخفاض مستويات فيتامين ب<sub>12 </sub>في الجسم لدى بعض الأشخاص الذين يتلقون هذا الدواء لفترة زمنية طويلة (أكثر عن 3 سنوات). يرجى منك إخبار طبيبك المعالج إذا عانيت من أعراض انخفاض مستويات فيتامين ب<sub>12 </sub>على سبيل المثال ضيق في التنفس، الشعور بالدوار، عدم انتظام ضربات القلب، ضعف العضلات، شحوب لون الجلد، الشعور بالتعب، تغيرات في المزاج والشعور بالتخدر والتنميل في الذراعين والساقين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; قد يحدث انخفاض مستويات المغنيسيوم<sub> </sub>في الجسم لدى بعض الأشخاص الذين يتلقون هذا الدواء لمدة لا تقل عن 3 أشهر. يرجى منك إخبار طبيبك المعالج على الفور إذا عانيت من أعراض انخفاض مستويات المغنيسيوم، بما في ذلك نوبات تشنجية، الشعور بالدوخة، عدم انتظام ضربات القلب، العصبية،&nbsp; ألم أو ضعف في العضلات، تشنجات في اليدين أو القدمين أو الأحبال الصوتية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ورم في المعدة (أورام حميدة في قاع المعدة). يزداد خطر تكون أحد أنواع أورام المعدة يعرف باسم أورام حميدة في قاع المعدة لدى الأشخاص الذين يتلقون العلاج باستخدام مثبطات مضخة البروتون لفترة زمنية طويلة، وبصفة خاصة بعد تلقي مثبطات مضخة البروتون لمدة أكثر من سنة واحدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; التفاعلات الجلدية الشديدة. من الممكن أن يسبب هذا الدواء في حدوث تفاعلات جلدية نادرة ولكنها شديدة والتي قد تؤثر على أي جزء من أجزاء الجسم لديك. قد تكون هذه التفاعلات الجلدية الخطيرة بحاجة لتلقي العلاج في المستشفى والتي وقد تكون مهددة للحياة:</p><p dir="RTL">الطفح الجلدي الذي يظهر على هيئة بثور أو تقشير أو نزيف في إحدى الأجزاء من الجلد (بما في ذلك الشفاه، العينين، الفم، الأنف، الأعضاء التناسلية، اليدين أو القدمين).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كما قد تعاني من الحمى، القشعريرة، آلام في الجسم، ضيق في التنفس أو تضخم في الغدد الليمفاوية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب التوقف عن تناول <strong>رايسك بلس</strong> والتواصل مع طبيبك المعالج على الفور. قد تكون هذه الأعراض هي العلامة الأولى لحدوث التفاعلات الجلدية الشديدة.</p><p dir="RTL"><strong>تتضمن التأثيرات الجانبية الأكثر شيوعاً الناجمة عن هذا الدواء على: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ألم في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; غثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; تقيؤ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; غازات</p><p dir="RTL"><strong><u>الإبلاغ عن التأثيرات الجانبية</u></strong></p><p dir="RTL">يرجى منك إخبار طبيبك المعالج، الصيدلي الذي تتعامل معه أو الممرض، في حال حدوث أياً من التأثيرات الجانبية، بما في ذلك أية تأثيرات جانبية يحتمل حدوثها ولم يتم ذكرها في هذه النشرة. كما يمكنك الإبلاغ عن التأثيرات الجانبية مباشرة عن طريق:</p><p dir="RTL">&nbsp;<strong>المملكة العربية السعودية:</strong></p><p dir="RTL"><strong>المركز الوطني للتيقظ الدوائي:</strong></p><p dir="RTL">-<strong> مركز الاتصال الموحد:</strong> 19999</p><p dir="RTL">-<strong> البريد الإلكتروني:</strong>&nbsp; npc.drug@sfda.gov.sa</p><p dir="RTL">- ا<strong>لموقع الإلكتروني:</strong> /https://ade.sfda.gov.sa</p><p dir="RTL"><strong>دول الخليج العربي الأخرى:</strong></p><p dir="RTL">- الرجاء الاتصال بالجهات الوطنية في كل دولة.</p><p dir="RTL">إن تسجيل التأثيرات الجانبية يساعد في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ الدواء بعيداً عن متناول ومرأى الأطفال.</p><p dir="RTL">يجب عدم تناول <strong>رايسك بلس</strong> بعد تاريخ انتهاء الصلاحية المذكور على العبوة والملصق الداخلي.</p><p dir="RTL">يحفظ في درجة حرارة أقل من 30&deg;م، بعيداً عن الضوء والرطوبة.</p><p dir="RTL">يجب إبقاء العبوة مغلقة بإحكام.</p><p dir="RTL">يجب عدم تناول <strong>رايسك بلس</strong> إذا لاحظت وجود علامات تلف واضحة.</p><p dir="RTL">يجب عدم التخلص من الأدوية عبر المياه المبتذلة (مياه الصرف الصحي) أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المواد الفعالة: أوميبرازول وبيكربونات الصوديوم&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL"><strong><u>برورايس </u></strong><strong><u>۲۰</u></strong><strong><u> ملغم / </u></strong><strong><u>۱۱۰۰</u></strong><strong><u> ملغم :</u></strong></p><p dir="RTL">تحتوي كل كبسولة جيلاتينية صلبة على: أوميبرازول ۲۰ ملغم / بيكربونات الصوديوم ۱۱۰۰ ملغم.</p><p dir="RTL">المواد الغير فعالة: كروس كارميلوز الصوديوم، ستيرات المغنيسيوم، ثنائي أكسيد التيتانيوم وجيلاتين .</p><p dir="RTL"><strong><u>برورايس ٤</u></strong><strong><u>۰</u></strong><strong><u> ملغم / </u></strong><strong><u>۱۱۰۰</u></strong><strong><u> ملغم :</u></strong></p><p dir="RTL">تحتوي كل كبسولة جيلاتيية صلبة على: أوميبرازول ٤۰ ملغم / بيكربونات الصوديوم ۱۱۰۰ ملغم.</p><p dir="RTL">المواد الغير فعالة: كروس كارميلوز الصوديوم، ستيرات المغنيسيوم، ثنائي أكسيد التيتانيوم وجيلاتين</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>رايسك بلس</strong> عبارة عن كبسولات جيلاتينية صلبة ذات حجم &laquo;00EL&raquo;، تحتوي على مسحوق أبيض اللون إلى أبيض مصفر.</p><p dir="RTL" style="text-align:right"><strong><u>رايسك بلس 20ملغم/1100ملغم:</u></strong></p><p dir="RTL" style="text-align:right"><strong>.&nbsp;&nbsp;&nbsp; </strong>الغطاء العلوي للكبسولة: أبيض داكن اللون مع رمز &laquo;جلفار&raquo; مطبوع باللون الأسود.</p><p dir="RTL" style="text-align:right"><strong>.&nbsp;&nbsp;&nbsp; </strong>الغطاء السفلي للكبسولة: أبيض داكن اللون مع رمز &laquo;OS20&raquo; مطبوع باللون الأسود.</p><p dir="RTL" style="text-align:right"><strong><u>رايسك بلس 40ملغم/1100ملغم:</u></strong></p><p dir="RTL" style="text-align:right"><strong>.&nbsp;&nbsp;&nbsp; </strong>الغطاء العلوي للكبسولة: أبيض داكن اللون مع رمز &laquo;جلفار&raquo; مطبوع باللون الأسود.</p><p dir="RTL" style="text-align:right"><strong>.&nbsp;&nbsp;&nbsp; </strong>الغطاء السفلي للكبسولة: أبيض داكن اللون مع رمز &laquo;OS40&raquo; مطبوع باللون الأسود.</p><p dir="RTL" style="text-align:right">تتوفر كبسولات<strong> رايسك بلس 20 ملغم/1100 ملغم </strong>في عبوات تحتوي على 14 أو 30 كبسولة جيلاتينية صلبة (في عبوة مصنعة من بولي إيثيلين عالي الكثافة).</p><p dir="RTL" style="text-align:right">تتوفر كبسولات<strong> رايسك بلس 40 ملغم/1100 ملغم </strong>في عبوات تحتوي على 14 أو 30 كبسولة جيلاتينية صلبة (في عبوة مصنعة من بولي إيثيلين عالي الكثافة).</p><p dir="RTL" style="text-align:right">* قد لا يتم تسويق جميع العبوات الدوائية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&quot;الخليج للصناعات الدوائية &quot; جلفار</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            22/7/2024م
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Risek Plus 40mg Capsules 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                

Each hard gelatin capsule contains:
Item No.	Material Name	Scale (mg/Capsule)
		
	Active Ingredient:	
1.		Omeprazole *	40.00
2.		Sodium bicarbonate*	1100.00
		
	Inactive Ingredients: 	
1.		Croscarmellose sodium 	40.00
2.		Magnesium stearate 	5.00
3.		Absolute Alcohol **	q.s. 
		
	Empty capsule:	
4.		Empty hard gelatin capsule, size: 00EL***               
	Cap: White opaque, printed “Julphar” radial in black. 
	Body: White opaque, printed “OS40” radial in black.	1 Nos.

Notes: 
* The quantity of Omeprazole and Sodium bicarbonate may be varied based on the assay value.
** Evaporates during manufacturing process and does not appear in the final product.
*** Composition of Capsule shell contains: Gelatin & Titanium dioxide. 

For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard Gelatin Capsules 
Description: Hard gelatin capsule, size “00EL” containing white to off- white powder 

Colours and Markings: 
	Cap: White opaque, printed “Julphar” radial in black. 
	Body: White opaque, printed “OS40” radial in black.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Risek Plus </strong>capsules are indicated in adults for the:</p><p>&sect;&nbsp;&nbsp; short-term treatment of active duodenal ulcer. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy.</p><p>&sect;&nbsp;&nbsp; short-term treatment (4 to 8 weeks) of active benign gastric ulcer.</p><p>&sect;&nbsp;&nbsp; treatment of heartburn and other symptoms associated with GERD for up to 4 weeks.</p><p>&sect;&nbsp;&nbsp; short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD which has been diagnosed by endoscopy in adults.</p><p>The efficacy of Omeprazole/ Sodium bicarbonate<strong> </strong>used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8-week courses of <strong>Risek Plus </strong>may be considered.</p><p>&sect;&nbsp;&nbsp; maintenance of healing of EE due to acid-mediated GERD. Controlled studies do not extend beyond 12 months.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Important Administration Instructions </u></strong></p><p>The sodium content of <strong>Risek Plus</strong> capsules should be taken into consideration when prescribing this product (See section 4.4).</p><p>Due to the sodium bicarbonate content of <strong>Risek Plus</strong>:</p><p>&sect; Do not substitute two 20mg <strong>Risek Plus</strong> capsules with one <strong>Risek Plus</strong> 40mg capsule.</p><p><strong><u>Dosage Regimen </u></strong></p><p>All recommended dosages are based upon omeprazole content.</p><p>Recommended Dosage Regimen of <strong>Risek Plus</strong> capsules in Adults by Indication:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:567px"><tbody><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Dosage of</strong><strong> </strong><strong>Risek Plus</strong> <strong>capsules</strong></p></td><td style="vertical-align:top"><p><strong>Treatment Duration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Treatment of Active Duodenal Ulcer</p></td><td style="vertical-align:top"><p>20 mg once daily</p></td><td style="vertical-align:top"><p>4 weeks<sup>1,2</sup></p></td></tr><tr><td style="vertical-align:top"><p>Treatment of Active Benign Gastric Ulcer</p></td><td style="vertical-align:top"><p>40 mg once daily</p></td><td style="vertical-align:top"><p>4 to 8 weeks</p></td></tr><tr><td style="vertical-align:top"><p>Treatment of Symptomatic GERD</p></td><td style="vertical-align:top"><p>20 mg once daily</p></td><td style="vertical-align:top"><p>Up to 4 weeks</p></td></tr><tr><td style="vertical-align:top"><p>Treatment of EE due to Acid-Mediated GERD</p></td><td style="vertical-align:top"><p>20 mg once daily</p></td><td style="vertical-align:top"><p>4 to 8 weeks<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p>Maintenance of Healing of EE due to Acid-Mediated GERD</p></td><td style="vertical-align:top"><p>20 mg once daily</p></td><td style="vertical-align:top"><p>Controlled studies do not extend beyond 12 months.</p></td></tr></tbody></table><p><sup>&nbsp;</sup></p><p><sup>1 </sup>Most patients heal within 4 weeks. Some patients may require an additional 4 weeks of therapy.</p><p><sup>2 </sup>The efficacy of Omeprazole/ Sodium bicarbonate used for longer than 8 weeks in patients with EE has not been established.</p><p>If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8-week courses of <strong>Risek Plus</strong> capsules may be considered.</p><p>&nbsp;</p><p><strong><u>Method of administration:</u></strong></p><p>&sect; Swallow capsules intact with water.</p><p>Do not open the capsule and do not administer with liquids other than water.</p><p>&sect; Take on an empty stomach at least one hour before a meal (See section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	The capsules are contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any component of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria. (See sections 4.4 and 4.8) 
	Proton pump inhibitors (PPIs), including Omeprazole/Sodium bicarbonate, are contraindicated in patients receiving rilpivirine containing products (See sections 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Presence of Gastric Malignancy</strong></p><p>In adults, symptomatic response to therapy with Omeprazole/Sodium bicarbonate does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing in adult patients who have a suboptimal response or an early symptomatic relapse after completing treatment with a proton pump inhibitor (PPI). In older patients, also consider an endoscopy.</p><p><strong>Acute Tubulointerstitial Nephritis</strong></p><p>Acute tubulointerstitial nephritis (TIN) has been observed in patients taking PPIs and may occur at any point during PPI therapy. Patients may present with varying signs and symptoms from symptomatic hypersensitivity reactions to non-specific symptoms of decreased renal function (e.g., malaise, nausea and anorexia). In reported case series, some patients were diagnosed on biopsy and in the absence of extra-renal manifestations (e.g., fever, rash or arthralgia). Acute tubulointerstitial nephritis can progress to renal failure.</p><p>Discontinue <strong>Risek Plus</strong> and evaluate patients with suspected acute TIN (See section 4.3) and appropriate treatment should be promptly initiated.</p><p><strong>Sodium Bicarbonate Content</strong></p><p><strong>Risek Plus</strong> capsule contains 1100mg of sodium bicarbonate.</p><p>Chronic administration of bicarbonate with calcium or milk can cause milk-alkali syndrome. Chronic use of sodium bicarbonate may lead to systemic alkalosis, and increased sodium intake can produce edema and weight gain.</p><p>The sodium content of <strong>Risek Plus</strong> products should be taken into consideration when administering to patients on a sodium-restricted diet or those at risk for developing congestive heart failure.</p><p>Avoid this medicine<strong> </strong>in patients with Bartter&rsquo;s syndrome, hypokalemia, hypocalcemia, and problems with acid-base balance.</p><p><strong><em>Clostridium difficile</em></strong><strong>-Associated Diarrhoea </strong></p><p>Published observational studies suggest that PPI therapy like Omeprazole/Sodium bicarbonate may be associated with an increased risk of&nbsp;<em>Clostridium difficile-</em>associated diarrhoea, especially in hospitalized patients. This diagnosis should be considered for diarrhoea that does not improve.&nbsp;(See section 4.8)</p><p>Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.</p><p><strong>Bone Fracture</strong></p><p>Several published observational studies suggest that proton pump inhibitor (PPI) therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. The risk of fracture was increased in patients who received high-dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer). Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Patients at risk for osteoporosis-related fractures should be managed according to the established treatment guidelines.&nbsp;(See sections&nbsp;4.2 and 4.8)</p><p><strong>Severe Cutaneous Adverse Reactions</strong></p><p>Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP) have been reported in association with the use of PPIs [see section 4.8]. Discontinue this medicine at the first signs or symptoms of severe cutaneous adverse reactions or other signs of hypersensitivity and consider further evaluation.</p><p><strong>Cutaneous and Systemic Lupus Erythematosus</strong></p><p>Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking PPIs, including omeprazole. These events have occurred as both new onset and an exacerbation of existing autoimmune disease. The majority of PPI-induced lupus erythematosus cases were CLE.</p><p>The most common form of CLE reported in patients treated with PPIs was subacute CLE (SCLE) and occurred within weeks to years after continuous drug therapy in patients ranging from infants to the elderly. Generally, histological findings were observed without organ involvement.</p><p>Systemic lupus erythematosus (SLE) is less commonly reported than CLE in patients receiving PPIs. PPI associated SLE is usually milder than non-drug induced SLE. Onset of SLE typically occurred within days to years after initiating treatment in patients ranging from young adults to the elderly. The majority of patients presented with rash; however, arthralgia and cytopenia were also reported.</p><p>Avoid administration of PPIs for longer than medically indicated. If signs or symptoms consistent with CLE or SLE are noted in patients receiving Omeprazole/Sodium bicarbonate, discontinue the drug and refer the patient to the appropriate specialist for evaluation. Most patients improve with discontinuation of the PPI alone in 4 to 12 weeks. Serological testing (e.g., ANA) may be positive and elevated serological test results may take longer to resolve than clinical manifestations.</p><p><strong>Interaction with Clopidogrel </strong></p><p>Avoid concomitant use of Omeprazole/Sodium bicarbonate with clopidogrel.</p><p>Clopidogrel is a prodrug. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. The metabolism of clopidogrel to its active metabolite can be impaired by use with concomitant medications, such as omeprazole, that interfere with CYP2C19 activity. Concomitant use of clopidogrel with 80mg omeprazole reduces the pharmacological activity of clopidogrel, even when administered 12 hours apart. When using Omeprazole/Sodium bicarbonate, consider alternative antiplatelet therapy.&nbsp;(See sections 4.5 and 5.2)<em> </em></p><p><strong>Cyanocobalamin (Vitamin B<sub>12</sub>) Deficiency</strong></p><p>Daily treatment with any acid-suppressing medications over a long period of time (e.g., longer than 3 years) may lead to malabsorption of cyanocobalamin (vitamin B<sub>12</sub>) caused by hypo- or achlorhydria. Rare reports of cyanocobalamin deficiency occurring with acid-suppressing therapy have been reported in the literature. This diagnosis should be considered if clinical symptoms consistent with cyanocobalamin deficiency are observed in patients treated with Omeprazole/Sodium bicarbonate.</p><p><strong>Hypomagnesemia</strong> <strong>and Mineral Metabolism</strong></p><p>Hypomagnesemia, symptomatic and asymptomatic, has been reported rarely in patients treated with PPIs for at least three months, in most cases after a year of therapy. Serious adverse events include tetany, arrhythmias, and seizures. Hypomagnesemiamay lead to hypocalcemia and/or hypokalemia and may exacerbate underlying hypocalcemia in at-risk patients. In most patients, treatment of hypomagnesemia required magnesium replacement and discontinuation of the PPI.</p><p>For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), healthcare professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically.&nbsp;(See sections 4.8)</p><p>Consider monitoring magnesium and calcium levels prior to initiation of omeprazole and Sodium Bicarbonate and periodically while on treatment in patients with a preexisting risk of hypocalcemia (e.g., hypoparathyroidism). Supplement with magnesium and/or calcium as necessary. If hypocalcemia is refractory to treatment, consider discontinuing the PPI.</p><p><strong>Interaction with St. John&rsquo;s Wort or Rifampin</strong></p><p>Drugs which induce CYP2C19 or CYP3A4 (such as St. John&rsquo;s wort or rifampin) can substantially decrease omeprazole concentrations&nbsp;(See sections 4.5)<em>.&nbsp;</em>Avoid concomitant use of Omeprazole/Sodium bicarbonate with St. John&rsquo;s wort or rifampin.</p><p><strong>Interactions with Investigations for Neuroendocrine Tumors </strong></p><p>Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors. Providers should temporarily stop Omeprazole/Sodium bicarbonate treatment for at least 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high. If serial tests are performed (e.g., for monitoring), the same commercial laboratory should be used for testing, as reference ranges between tests may vary.&nbsp;(See sections 4.5)</p><p><strong>Interaction with Methotrexate</strong></p><p>Literature suggests that concomitant use of PPIs with methotrexate (primarily at high dose) may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities. In high-dose methotrexate administration, a temporary withdrawal of the PPI may be considered in some patients. (See sections 4.5).</p><p><strong>Fundic Gland Polyps</strong></p><p>PPI use is associated with an increased risk of fundic gland polyps that increases with long-term use, especially beyond one year. Most PPIs users who developed fundic gland polyps were asymptomatic and fundic gland polyps were identified incidentally on endoscopy. Use the shortest duration of PPI therapy appropriate to the condition being treated.</p><p><strong><u>Special Population</u></strong></p><p><strong>Paediatric Use</strong></p><p>Safety and effectiveness of Omeprazole/Sodium bicarbonate have not been established in paediatric patients.</p><p><strong>Geriatric Use</strong></p><p>Clinical trials have shown there were no differences in safety and effectiveness between the elderly and younger subjects.&nbsp; Other reported clinical experience has not identified differences in response between the elderly and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.</p><p>Pharmacokinetic studies with buffered omeprazole have shown the elimination rate was somewhat decreased in the elderly and bioavailability was increased. The plasma clearance of omeprazole was 250 mL/min (about half that of young subjects). The plasma half-life averaged one hour, about twice that in nonelderly, healthy subjects taking Omeprazole/Sodium bicarbonate. However, no dosage adjustment is necessary in the elderly. (See section 5.2)</p><p><strong>Hepatic Impairment</strong></p><p>In patients with hepatic impairment (Child-Pugh Class A, B, or C) exposure to omeprazole substantially increased compared to healthy subjects. Avoid use of Omeprazole/Sodium bicarbonate in patients with hepatic impairment for maintenance of healing of erosive esophagitis (See section 5.2)</p><p><strong>Asian Population </strong></p><p>In studies of healthy subjects, Asians had approximately a four-fold higher exposure than Caucasians. Avoid use of Omeprazole/Sodium bicarbonate in Asian patients for maintenance of healing of erosive esophagitis. (See section 5.2)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The below information include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with omeprazole and instructions for preventing or managing them.</p><p><strong><u>Clinically Relevant Interactions Affecting Drugs Co-Administered with Omeprazole and Interaction with Diagnostics</u></strong></p><p><strong>Antiretrovirals</strong></p><p>The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known.</p><p>&sect; Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir and nelfinavir) when used concomitantly with omeprazole may reduce antiviral effect and promote the development of drug resistance (see section 5.2).</p><p>&sect; Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with omeprazole may increase toxicity) (see section 5.2).</p><p>&sect; There are other antiretroviral drugs which do not result in clinically relevant interactions with omeprazole.</p><p><strong>&nbsp;</strong></p><p><strong>Warfarin</strong></p><p>Increased INR and prothrombin time in patients receiving PPIs including omeprazole, and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death.</p><p><strong>Methotrexate</strong></p><p>Concomitant use of omeprazole with methotrexate (primarily at high dose) may elevate and prolong serum concentrations of methotrexate and/or its metabolite hydroxymethotrexate, possibly leading to methotrexate toxicities. No formal drug interaction studies of high-dose methotrexate with PPIs have been conducted (See section 4.4).</p><p><strong>CYP2C19 Substrates (e.g., clopidogrel, citalopram, cilostazol, phenytoin, diazepam)</strong></p><p><em>Clopidogrel:</em><strong> </strong>Concomitant use of omeprazole 80 mg results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition (See section 5.2).</p><p>There are no adequate combination studies of a lower dose of omeprazole or a higher dose of clopidogrel in comparison with the approved dose of clopidogrel<em>.</em></p><p><em>Citalopram:</em><strong> </strong>Increased exposure of citalopram leading to an increased risk of QT prolongation.</p><p><em>Cilostazol: </em>Increased exposure of one of the active metabolites of cilostazol (3,4-dihydro-cilostazol) (See section 5.2).</p><p><em>Phenytoin:</em><strong> </strong>Potential for increased exposure of phenytoin.</p><p><em>Diazepam: </em>Increased exposure of diazepam.</p><p><strong>Digoxin</strong></p><p>Potential for increased exposure of digoxin.</p><p><strong>Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole)</strong></p><p>Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.</p><p><strong>Tacrolimus</strong></p><p>Potential for increased exposure of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19</p><p><strong>Interactions with Investigations of Neuroendocrine Tumors</strong></p><p>Serum chromogranin A (CgA) levels increase secondary to PPI-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors (See sections 4.4 and 5.1).</p><p><strong>Interaction with Secretin Stimulation Test</strong></p><p>Hyper-response in gastrin secretion in response to secretin stimulation test, falsely suggesting gastrinoma.</p><p><strong>False Positive Urine Tests for THC</strong></p><p>There have been reports of false positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving PPIs.</p><p><strong>Other</strong></p><p>There have been clinical reports of interactions with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram).</p><p><strong><u>Clinically Relevant Interactions Affecting Omeprazole When Co-Administered with Other Drugs</u></strong></p><p><strong>CYP2C19 or CYP3A4 Inducers</strong></p><p>Decreased exposure of omeprazole when used concomitantly with strong inducers. (See section 4.4)</p><p><strong>CYP2C19 or CYP3A4 Inhibitors</strong></p><p>Increased exposure of omeprazole.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p><strong>Risk Summary</strong></p><p>There are no adequate and well-controlled studies with Omeprazole/Sodium bicarbonate in pregnant women. <strong>Risek Plus</strong> capsules contain omeprazole and sodium bicarbonate.</p><p><em>Omeprazole&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p>There are no adequate and well-controlled studies with omeprazole in pregnant women. Available epidemiologic data fail to demonstrate an increased risk of major congenital malformations or other adverse pregnancy outcomes with first trimester omeprazole use. Reproduction studies in rats and rabbits resulted in dose-dependent embryo-lethality at omeprazole doses that were approximately 3.4 to 34 times an oral human dose of 40 mg (based on a body surface area for a 60 kg person).</p><p>Teratogenicity was not observed in animal reproduction studies with administration of oral esomeprazole (an enantiomer of omeprazole) magnesium in rats and rabbits during organogenesis with doses about 68 times and 42 times, respectively, an oral human dose of 40mg esomeprazole or 40mg omeprazole (based on body surface area for a 60 kg person). Changes in bone morphology were observed in offspring of rats dosed through most of pregnancy and lactation at doses equal to or greater than approximately 34 times an oral human dose of 40mg esomeprazole or 40mg omeprazole. When maternal administration was confined to gestation only, there were no effects on bone physeal morphology in the offspring at any age.</p><p><em>Sodium Bicarbonate</em></p><p>Available data with sodium bicarbonate use in pregnant women are insufficient to identify a drug associated risk of major birth defects or miscarriage. Published animal studies report that sodium bicarbonate administered to rats, mice or rabbits during pregnancy did not cause adverse developmental effects in offspring.</p><p>The estimated background risks of major birth defects and miscarriage for the indicated population are unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes.</p><p><strong><u>Lactation</u></strong></p><p><strong>Risk Summary</strong></p><p>Available data from the published literature suggest both components of the capsules, omeprazole and sodium bicarbonate, are present in human milk. There are no clinical data on the effects of omeprazole or sodium bicarbonate on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother&#39;s clinical need for the capsules and any potential adverse effects on the breastfed infant from the capsules or from the underlying maternal condition.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following serious adverse reactions are described above in section 4.4 (Special warnings and precautions for use)</p><p>&sect;&nbsp; Acute Tubulointerstitial Nephritis&nbsp;</p><p>&sect;&nbsp; <em>Clostridium difficile</em>-Associated Diarrhoea&nbsp;</p><p>&sect;&nbsp; Bone Fracture&nbsp;</p><p>&sect;&nbsp; Cutaneous and Systemic Lupus Erythematosus&nbsp;</p><p>&sect;&nbsp; Cyanocobalamin (Vitamin B<sub>12</sub>) Deficiency<em>&nbsp;</em></p><p>&sect;&nbsp; Hypomagnesemia&nbsp;and mineral metabolism</p><p>&sect;&nbsp; Fundic Gland Polyps&nbsp;</p><p>&nbsp;</p><p><u>Post-marketing Experience</u></p><p>The following adverse reactions have been identified during post-approval use of omeprazole and sodium bicarbonate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p><strong><u>Omeprazole</u></strong></p><p><strong>Body as a Whole</strong><em>:</em>&nbsp;Hypersensitivity reactions, including anaphylaxis, anaphylactic shock, angioedema, bronchospasm, urticaria (see also Skin below), fever, pain, fatigue, malaise, and systemic lupus erythematosus.</p><p><strong><em>Cardiovascular:</em></strong>&nbsp;Chest pain or angina, tachycardia, bradycardia, palpitation, elevated blood pressure, and peripheral edema.</p><p><strong><em>Gastrointestinal:</em></strong>&nbsp;Pancreatitis (some fatal), anorexia, irritable colon, flatulence, fecal discoloration, esophageal candidiasis, mucosal atrophy of the tongue, dry mouth, stomatitis, abdominal swelling and fundic gland polyps. Gastroduodenal carcinoids have been reported in patients with Zollinger-Ellison syndrome on long-term treatment with omeprazole. This finding is believed to be a manifestation of the underlying condition, which is known to be associated with such tumors.</p><p><strong><em>Hepatic:</em></strong>&nbsp;Mild and, rarely, marked elevations of liver function tests [ALT (SGPT), AST (SGOT), ᵞ-glutamyl transpeptidase, alkaline phosphatase, and bilirubin (jaundice)]. In rare instances, overt liver disease has occurred, including hepatocellular, cholestatic, or mixed hepatitis, liver necrosis (some fatal), hepatic failure (some fatal), and hepatic encephalopathy.</p><p><strong><em>Infections and Infestations:</em></strong><em> Clostridium difficile</em>-associated diarrhoea.</p><p><strong><em>Metabolism and Nutritional Disorders</em></strong><em>:</em>&nbsp;Hypomagnesemia, hypocalcemia, hypokalemia (see</p><p>section 4.4), hyponatremia, hypoglycemia, and weight gain.</p><p><strong><em>Musculoskeletal:</em></strong>&nbsp;Muscle cramps, myalgia, muscle weakness, joint pain, bone fracture, and leg pain.</p><p><strong><em>Nervous System/Psychiatric</em></strong><em>:</em>&nbsp;Psychic disturbances including depression, agitation, aggression, hallucinations, confusion, insomnia, nervousness, tremors, apathy, somnolence, anxiety, dream abnormalities; vertigo; paresthesia; and hemifacial dysesthesia.</p><p><strong><em>Respiratory:</em></strong>&nbsp;Epistaxis, pharyngeal pain.</p><p><strong><em>Skin:</em></strong>&nbsp;Severe generalized skin reactions including toxic epidermal necrolysis TEN (some fatal), SJS, DRESS, AGEP. cutaneous lupus erythematosus and erythema multiforme (some severe); purpura and/or petechiae (some with rechallenge); skin inflammation, urticaria, angioedema, pruritus, photosensitivity, alopecia, dry skin, and hyperhidrosis.</p><p><strong><em>Special Senses:</em></strong>&nbsp;Tinnitus, taste perversion.</p><p><strong><em>Ocular:</em></strong>&nbsp;Blurred vision, ocular irritation, dry eye syndrome, optic atrophy, anterior ischemic optic neuropathy, optic neuritis, and double vision.</p><p><strong><em>Urogenital</em></strong><em>:</em>&nbsp;Rarely, tubulointerstitial nephritis (with possible progression to renal failure), urinary tract infection, microscopic pyuria, urinary frequency, elevated serum creatinine, proteinuria, hematuria, glycosuria, testicular pain, gynecomastia and erectile dysfunction.</p><p><strong><em>Hematologic</em></strong><em>:</em>&nbsp;Rare instances of pancytopenia, agranulocytosis (some fatal), thrombocytopenia, neutropenia, leukopenia, anemia, leukocytosis, and hemolytic anemia have been reported.</p><p><strong><u>Sodium Bicarbonate</u></strong></p><p>Metabolic alkalosis, seizures, and tetany.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>To report any side effect(s):</u></strong></p><p>&sect; <strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>SFDA Call Centre:</strong> 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>E-mail:</strong> npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Website:</strong> https://ade.sfda.gov.sa/</p><p>&sect; <strong>Other GCC States: </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Omeprazole</u></strong></p><p>Reports have been received of overdosage with omeprazole in humans. Doses ranged up to 2400mg (120 times the usual recommended clinical dose). Manifestations were variable, but included confusion, drowsiness, blurred vision, tachycardia, nausea, vomiting, diaphoresis, flushing, headache, dry mouth, and other adverse reactions similar to those seen in clinical experience with the recommended dosage (See section 4.8)<em>.&nbsp;</em>Symptoms were transient, and no serious clinical outcome has been reported when omeprazole was taken alone. No specific antidote for omeprazole overdosage is known. Omeprazole is extensively protein bound and is, therefore, not readily dialyzable. In the event of overdosage, treatment should be symptomatic and supportive.</p><p><strong><u>Sodium Bicarbonate</u></strong></p><p>Overdosage of sodium bicarbonate can cause electrolyte abnormalities (hypocalcemia, hypokalemia, hypernatremia), metabolic alkalosis, and seizures. Institute supportive care and correct electrolyte abnormalities.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Risek Plus</strong> (omeprazole and sodium bicarbonate) is a combination of omeprazole, a proton-pump inhibitor, and sodium bicarbonate, an antacid.</p><p><strong><u>Mechanism of Action</u></strong></p><p>Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus.</p><p><strong><u>Antisecretory Activity</u></strong></p><p>Results from a separate pharmacokinetic/pharmacodynamics (PK/PD) study of antisecretory effect on repeated once-daily dosing of 40mg/1100mg and 20mg/1100mg of Omeprazole/Sodium bicarbonate capsules in healthy subjects show similar effects in general PD parameters as those for Omeprazole/Sodium bicarbonate for oral suspension 40mg/1680mg and 20mg/1680 mg, respectively. &nbsp;</p><p>The antisecretory effect lasts longer than would be expected from the very short (1 hour) plasma half-life, apparently due to irreversible binding to the parietal H+/K+ ATPase enzyme.</p><p><strong><u>Enterochromaffin-like (ECL) Cell Effects</u></strong></p><p>Human gastric biopsy specimens have been obtained from more than 3000 patients treated with omeprazole in long-term clinical trials. The incidence of ECL cell hyperplasia in these studies increased with time; however, no case of ECL cell carcinoids, dysplasia, or neoplasia has been found in these patients. These studies are of insufficient duration and size to rule out the possible influence of long-term administration of omeprazole on the development of any premalignant or malignant conditions.</p><p><strong><u>Serum Gastrin Effects </u></strong></p><p>In studies involving more than 200 patients, serum gastrin levels increased during the first 1 to 2 weeks of once-daily administration of therapeutic doses of omeprazole in parallel with inhibition of acid secretion. No further increase in serum gastrin occurred with continued treatment. In comparison with histamine H<sub>2</sub>-receptor antagonists, the median increases produced by 20mg doses of omeprazole were higher (1.3 to 3.6-fold vs. 1.1- to 1.8-fold increase). Gastrin values returned to pretreatment levels, usually within 1 to 2 weeks after discontinuation of therapy.</p><p>Increased gastrin causes enterochromaffin-like cell hyperplasia and increased serum Chromogranin A (CgA) levels. The increased CgA levels may cause false positive results in diagnostic investigations for neuroendocrine tumors&nbsp;(see section 4.4).</p><p><strong><u>Other Effects</u></strong></p><p>Systemic effects of omeprazole in the central nervous system (CNS), cardiovascular and respiratory systems have not been found to date. Omeprazole, given in oral doses of 30 or 40mg for 2 to 4 weeks, had no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.</p><p>No effect on gastric emptying of the solid and liquid components of a test meal was demonstrated after a single dose of omeprazole 90mg. In healthy subjects, a single intravenous dose of omeprazole (0.35mg/kg) had no effect on intrinsic factor secretion. No systematic dose-dependent effect has been observed on basal or stimulated pepsin output in humans. However, when intragastric pH is maintained at 4.0 or above, basal pepsin output is low, and pepsin activity is decreased.</p><p>As do other agents that elevate intragastric pH, omeprazole administered for 14 days in healthy subjects produced a significant increase in the intragastric concentrations of viable bacteria. The pattern of the bacterial species was unchanged from that commonly found in saliva. All changes resolved within three days of stopping treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Absorption</u></strong></p><p>The table below show the systemic exposures and the time reach peak concentration (T<sub>max</sub>) of omeprazole in healthy subjects following administration of Omeprazole/Sodium bicarbonate capsules, on an empty stomach one hour prior to a meal.</p><p><strong>Arithmetic Mean (CV%) of the Systemic Exposures (C<sub>max</sub>, AUC) and T<sub>max</sub> of Omeprazole after a Single Oral Dose and Multiple Once-Daily Doses of Omeprazole/Sodium bicarbonate Capsules</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:96%"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td colspan="3" style="vertical-align:top"><p>20mg Omeprazole/Sodium bicarbonate capsules</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Day 1</p></td><td style="vertical-align:top"><p>Day 7</p></td><td style="vertical-align:top"><p>% Change (Day 7/Day 1)</p></td></tr><tr><td style="vertical-align:top"><p><sub>Cmax&nbsp;</sub>(ng/mL)</p></td><td style="vertical-align:top"><p>498.1 (50.9)</p></td><td style="vertical-align:top"><p>679.8 (44.0)</p></td><td style="vertical-align:top"><p>36</p></td></tr><tr><td style="vertical-align:top"><p>T<sub>max</sub>&nbsp;(hr) [min &ndash; max]</p></td><td style="vertical-align:top"><p>0.61 [0.25-1.5]</p></td><td style="vertical-align:top"><p>0.82 [0.25-1.5]</p></td><td style="vertical-align:top"><p>n.a.</p></td></tr><tr><td style="vertical-align:top"><p>AUC0-inf*&nbsp;(ng&bull;hr/mL)</p></td><td style="vertical-align:top"><p>509.7 (60.5)</p></td><td style="vertical-align:top"><p>1029 (67.9)</p></td><td style="vertical-align:top"><p>102</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:96%"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td colspan="3" style="vertical-align:top"><p>40mg Omeprazole/Sodium bicarbonate capsules</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Day 1</p></td><td style="vertical-align:top"><p>Day 7</p></td><td style="vertical-align:top"><p>% Change (Day 7/Day 1)</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub>&nbsp;(ng/mL)</p></td><td style="vertical-align:top"><p>1154 (53.0)</p></td><td style="vertical-align:top"><p>1526 (48.7)</p></td><td style="vertical-align:top"><p>32</p></td></tr><tr><td style="vertical-align:top"><p>T<sub>max</sub>&nbsp;(hr) [min &ndash; max]</p></td><td style="vertical-align:top"><p>0.56 [0.25-1.5]</p></td><td style="vertical-align:top"><p>0.97 [0.25-3.5]</p></td><td style="vertical-align:top"><p>n.a.</p></td></tr><tr><td style="vertical-align:top"><p>AUC0-inf*&nbsp;(ng&bull;hr/mL)</p></td><td style="vertical-align:top"><p>1882 (120)</p></td><td style="vertical-align:top"><p>3866 (83.3)</p></td><td style="vertical-align:top"><p>105</p></td></tr></tbody></table><p>n.a.: not applicable</p><p>*&nbsp;AUC<sub>0-24h</sub>&nbsp;was used on Day 7</p><p>Following single or repeated once-daily dosing, peak plasma concentrations (C<sub>max</sub>) of omeprazole from Omeprazole/Sodium bicarbonate capsules were approximately proportional from 20 to 40mg doses. A greater than dose proportional increase in mean steady-state AUC (more than three-fold increase on Day 7) was observed when doubling the dose to 40mg. The bioavailability of omeprazole from Omeprazole/Sodium bicarbonate increases upon repeated administration. The percent changes in C<sub>max</sub>&nbsp;and AUC between steady-state (Day 7) and single dose (Day 1) indicate omeprazole is a time-dependent autoinhibitor of CYP2C19.&nbsp;</p><p>When Omeprazole/Sodium bicarbonate capsule 40mg is administered one hour after a meal, the omeprazole AUC is reduced by approximately 27% and 22%, respectively, relative to administration one hour prior to a meal&nbsp;(See section 4.2).</p><p><strong><u>Distribution</u></strong></p><p>Omeprazole is bound to plasma proteins. Protein binding is approximately 95%.</p><p><strong><u>Elimination</u></strong><br /><strong>Metabolism</strong></p><p>Omeprazole is extensively metabolized by the cytochrome P450 (CYP) enzyme system. The major part of its metabolism is dependent on the polymorphically expressed CYP2C19<em>,</em> responsible for the formation of hydroxyomeprazole, the major metabolite in plasma. The remaining part is dependent on another specific isoform, CYP3A4, responsible for the formation of omeprazole sulphone.</p><p>The mean plasma omeprazole half-life following administration of the capsule in healthy subjects is approximately 1 hour (range 0.4 to 4.2 hours), and the total body clearance is 500 to 600 mL/min.</p><p><strong>Excretion</strong></p><p>Following single-dose oral administration of a buffered solution of omeprazole, the majority of the dose (about 77%) is eliminated in urine as at least six metabolites. Two metabolites have been identified as hydroxyomeprazole and the corresponding carboxylic acid. The remainder of the dose was recoverable in feces. This implies a significant biliary excretion of the metabolites of omeprazole. Three metabolites have been identified in plasma &ndash; the sulfide and sulfone derivatives of omeprazole, and hydroxyomeprazole. These metabolites have very little or no antisecretory activity.</p><p><strong><u>Specific Populations</u></strong></p><p><em>Geriatric Patients</em></p><p>The elimination rate of omeprazole was somewhat decreased in the elderly, and bioavailability was increased. Omeprazole was 76% bioavailable when a single 40mg oral dose of omeprazole (buffered solution) was administered to healthy elderly subjects versus 58% in young subjects given the same dose. Nearly 70% of the dose was recovered in urine as metabolites of omeprazole, and no unchanged drug was detected. The plasma clearance of omeprazole was 250&nbsp;mL/min (about half that of young subjects), and its plasma half-life averaged one hour, similar to that of young healthy subjects.</p><p><em>Male and Female Patients</em></p><p>There are no known differences in the absorption or excretion of omeprazole between males and females.</p><p><em>Patients with Renal Impairment</em></p><p>In patients with chronic renal impairment (creatinine clearance between 10 and 62 mL/min/1.73 m<sup>2</sup>), the disposition of omeprazole was very similar to that in healthy subjects, although there was a slight increase in bioavailability. Because urinary excretion is a primary route of excretion of omeprazole metabolites, their elimination slowed in proportion to the decreased creatinine clearance. This increase in bioavailability is not considered to be clinically meaningful.</p><p><em>Patients with Hepatic Impairment</em></p><p>In patients with chronic hepatic disease classified as Child-Pugh Class A (n=3), B (n=4) and C (n=1), the bioavailability of omeprazole increased to approximately 100% compared to healthy subjects, reflecting decreased first-pass effect, and the plasma half-life of the drug increased to nearly 3 hours compared to the in healthy subjects of 0.5 to 1 hour. Plasma clearance averaged 70 mL/min, compared to a value of 500 to 600 mL/min in healthy subjects&nbsp;(See section 4.4 &ndash; Special population).</p><p><strong><u>Drug Interactions Studies</u></strong></p><p><strong>Effect of Omeprazole on Other Drugs</strong></p><p>Omeprazole is a time-dependent inhibitor of CYP2C19 and can increase the systemic exposure of co-administered drugs that are CYP2C19 substrates. In addition, administration of omeprazole increases intragastric pH and can alter the systemic exposure of certain drugs that exhibit pH-dependent solubility (see section 4.5).</p><p><em>Antiretrovirals:</em></p><p>For some antiretroviral drugs, such as rilpivirine, atazanavir and nelfinavir, decreased serum concentrations have been reported when given together with omeprazole (see section 4.5).</p><p><em>Rilpivirine</em>:</p><p>Following multiple doses of rilpivirine (150 mg, daily) and omeprazole (20 mg, daily), AUC was decreased by 40%, C<sub>max</sub> by 40%, and C<sub>min</sub> by 33% for rilpivirine.</p><p><em>Nelfinavir</em>:</p><p>Following multiple doses of nelfinavir (1250 mg, twice daily) and omeprazole (40 mg daily), AUC was decreased by 36% and 92%, C<sub>max </sub>by 37% and 89% and C<sub>min</sub> by 39% and 75% respectively for nelfinavir and M8.</p><p><em>Atazanavir: </em></p><p>Following multiple doses of atazanavir (400 mg, daily) and omeprazole (40 mg, daily, 2 hours before atazanavir), AUC was decreased by 94%, C<sub>max</sub> by 96%, and C<sub>min</sub> by 95%.</p><p><em>Saquinavir: </em></p><p>Following multiple dosing of saquinavir/ritonavir (1000/100 mg) twice daily for 15 days with omeprazole 40 mg daily co-administered days 11 to 15.</p><p>AUC was increased by 82%, C<sub>max</sub> by 75%, and C<sub>min</sub> by 106%. The mechanism behind this interaction is not fully elucidated. Therefore, clinical and laboratory monitoring for saquinavir toxicity is recommended during concurrent use with omeprazole.</p><p><em>Clopidogrel</em></p><p>In a crossover clinical study, 72 healthy subjects were administered clopidogrel (300 mg loading dose followed by 75 mg per day) alone and with omeprazole (80 mg at the same time as clopidogrel) for 5 days. The exposure to the active metabolite of clopidogrel was decreased by 46% (Day 1) and 42% (Day 5) when clopidogrel and omeprazole were administered together.</p><p>Results from another crossover study in healthy subjects showed a similar pharmacokinetic interaction between clopidogrel (300 mg loading dose/75 mg daily maintenance dose) and omeprazole 80 mg daily when co-administered for 30 days.</p><p>Exposure to the active metabolite of clopidogrel was reduced by 41% to 46% over this time period.</p><p>In another study, 72 healthy subjects were given the same doses of clopidogrel and 80 mg omeprazole, but the drugs were administered 12 hours apart; the results were similar, indicating that administering clopidogrel and omeprazole at different times does not prevent their interaction (see sections 4.4 and 4.5).</p><p><em>Mycophenolate Mofetil</em></p><p>Administration of omeprazole 20 mg twice daily for 4 days and a single 1000 mg dose of MMF approximately one hour after the last dose of omeprazole to 12 healthy subjects in a crossover study resulted in a 52% reduction in the C and 23% reduction in the AUC of MPA (see section 4.5).</p><p><em>Cilostazol</em></p><p>Omeprazole acts as an inhibitor of CYP2C19. Omeprazole, given in doses of 40 mg daily for one week to 20 healthy subjects in crossover study, increased C<sub>max</sub> and AUC of cilostazol by 18% and 26% respectively. The C<sub>max</sub> and AUC of one of the active metabolites, 3,4-dihydro-cilostazol, which has 4 to 7 times the activity of cilostazol, were increased by 29% and 69%, respectively. Co-administration of cilostazol with omeprazole is expected to increase concentrations of cilostazol and the above mentioned active metabolite (see section 4.5).</p><p><em>Diazepam</em></p><p>Concomitant administration of omeprazole 20 mg once daily and diazepam 0.1 mg/kg given intravenously resulted in 27% decrease in clearance and 36% increase in diazepam half-life (see section 4.5).</p><p><em>Digoxin</em></p><p>Concomitant administration of omeprazole 20 mg once daily and digoxin in healthy subjects increased the bioavailability of digoxin by 10% (30% in two subjects) (see section 4.5).</p><p><strong>&nbsp;</strong></p><p><strong>Effect of Other Drugs on Omeprazole</strong></p><p><em>Voriconazole</em></p><p>Concomitant administration of omeprazole and voriconazole (a combined inhibitor of CYP2C19 and CYP3A4) resulted in more than doubling of the omeprazole exposure.</p><p>When voriconazole (400 mg every 12 hours for one day, followed by 200 mg once daily for 6 days) was given with omeprazole (40 mg once daily for 7 days) to healthy subjects, the steady-state C<sub>max</sub> and AUC0-24 of omeprazole significantly increased: an average of 2 times (90% CI: 1.8, 2.6) and 4 times (90% CI: 3.3, 4.4), respectively, as compared to when omeprazole was given without voriconazole&nbsp; (see section 4.5)<em>. </em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Carcinogenesis, Mutagenesis, Impairment of Fertility</strong></p><p>In two 24-month carcinogenicity studies in rats, omeprazole at daily doses of 1.7, 3.4, 13.8, 44 and 140.8 mg/kg/day (approximately 0.4 to 34.2 times the human dose of 40 mg/day on a body surface area basis) produced gastric ECL cell carcinoids in a dose-related manner in both male and female rats; the incidence of this effect was markedly higher in female rats, which had higher blood levels of omeprazole. Gastric carcinoids seldom occur in the untreated rat. In addition, ECL cell hyperplasia was present in all treated groups of both sexes. In one of these studies, female rats were treated with 13.8 mg omeprazole/kg/day (approximately 3.36 times the human dose of 40 mg/day on a body surface area basis) for one year, then followed for an additional year without the drug. No carcinoids were seen in these rats. An increased incidence of treatment-related ECL cell hyperplasia was observed at the end of one year (94% treated versus 10% controls). By the second year the difference between treated and control rats was much smaller (46% versus 26%) but still showed more hyperplasia in the treated group. Gastric adenocarcinoma was seen in one rat (2%). No similar tumor was seen in male or female rats treated for two years. For this strain of rat no similar tumor has been noted historically, but a finding involving only one tumor is difficult to interpret. In a 52-week toxicity study in Sprague Dawley rats, brain astrocytomas were found in a small number of males that received omeprazole at dose levels of 0.4, 2, and 16&nbsp;mg/kg/day (about 0.1 to 3.9 times the human dose of 40 mg/day on a body surface area basis). No astrocytomas were observed in female rats in this study. In a 2-year carcinogenicity study in Sprague Dawley rats, no astrocytomas were found in males and females at the high dose of 140.8 mg/kg/day (about 34 times the human dose of 40 mg/day on a body surface area basis). A 78-week mouse carcinogenicity study of omeprazole did not show increased tumor occurrence, but the study was not conclusive. A 26-week p53 (+/-) transgenic mouse carcinogenicity study was not positive.</p><p>Omeprazole was positive for clastogenic effects in an in vitro human lymphocyte chromosomal aberration assay, in one of two in vivo mouse micronucleus tests, and in an in vivo bone marrow cell chromosomal aberration assay. Omeprazole was negative in the in vitro Ames test, an in vitro mouse lymphoma cell forward mutation assay and an in vivo rat liver DNA damage assay.</p><p>In a 24-month carcinogenicity studies in rats, a dose-related significant increase in gastric carcinoid tumors and ECL cell hyperplasia was observed in both male and female animals<em>.&nbsp;</em>Carcinoid tumors have also been observed in rats subjected to fundectomy or long-term treatment with other PPIs or high doses of H<sub>2</sub>-receptor antagonists.</p><p>Omeprazole at oral doses up to 138 mg/kg/day (about 33.6 times the human dose of 40 mg/day on a body surface area basis) was found to have no effect on the fertility and general reproductive performance in rats.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:538px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong><u>Inactive Ingredients: </u></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.</p></td><td style="vertical-align:top"><p>Croscarmellose sodium</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.</p></td><td style="vertical-align:top"><p>Magnesium stearate</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp; &nbsp; &nbsp;3.</p></td><td style="vertical-align:top"><p>Absolute Alcohol *</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong><u>Empty capsule:</u></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &nbsp; &nbsp; &nbsp;4.</p></td><td colspan="2" style="vertical-align:top"><p>Empty hard gelatin capsule, size: 00EL**</p><p>&sect; Cap: White opaque, printed &ldquo;Julphar&rdquo; radial in black.</p><p>&sect; Body: White opaque, printed &ldquo;OS40&rdquo; radial in black.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><u>Notes</u></strong>:</p><p>* Evaporates during manufacturing process and does not appear in the final product.</p><p>** Composition of Capsule shell contains: Gelatin &amp; Titanium dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months from the date of manufacturing.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C, protected from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&sect; <strong>Pack of 14 Capsules</strong>: 14 Capsules in a HDPE plastic bottle with cotton and closed with a plastic cap 3G silica gel CRC packed in a carton, along with a leaflet.</p><p>&sect; <strong>Pack of 30 Capsules</strong>: 30 in a HDPE plastic bottle with cotton and closed with a plastic cap 3G silica gel CRC packed in a carton, along with a leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep container tightly closed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gulf Pharmaceutical Industries - Julphar
Digdaga, Airport Street.
Ras Al Khaimah - United Arab Emirates.
P.O. Box 997
Tel. No.: (9717) 2 461 461
Fax No.: (9717) 2 462 462

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                22. May. 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>